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I schemic preconditioning has been identified as a suc-cessful strategy for improving the preservation of car-
diac allografts.1,2 However, concerns about the imple-
mentation of an ischemic-type stimulus3 have led to the
search for preconditioning-mimetic pharmacologic
agents. Because the end effectors of the ischemic pre-
conditioning pathway are likely to be the adenosine
triphosphate-sensitive potassium channels (KATP) and,
more specifically, those of mitochondria,4 selective open-
ers of these channels, such as diazoxide, have emerged as
potential cardioprotective agents5,6 that can closely dupli-
Objective: This study was designed to compare ischemic preconditioning
with opening of mitochondrial adenosine triphosphate-sensitive potassium
channels and Na+/H+ exchange inhibition in an isolated heart model of cold
storage, simulating the situation of cardiac allografts.
Methods: Sixty-seven isolated isovolumic buffer-perfused rat hearts were
arrested with and stored in Celsior solution (Imtix-Sangstat) at 4°C for 4 hours
before a 2-hour reperfusion. Group I hearts served as controls and were arrest-
ed with and stored in Celsior solution. In group II, hearts were preconditioned
by two 5-minute episodes of global ischemia, each separated by 5 minutes of
reperfusion before arrest with Celsior solution. Group III hearts were arrested
with and stored in Celsior solution supplemented with 100 µmol/L of the mito-
chondrial adenosine triphosphate-sensitive potassium channel opener diazox-
ide. In group IV, hearts received an infusion of diazoxide (30 µmol/L) during
the first 15 minutes of reperfusion. Group V hearts underwent a protocol com-
bining both interventions used in groups III and IV. In group VI, hearts were
arrested with and stored in Celsior solution supplemented with 1 µmol/L of the
Na+/H+ exchange inhibitor cariporide. Group VII hearts received an infusion
of cariporide (1 µmol/L) during the first 15 minutes of reperfusion. In group
VIII, hearts underwent a protocol combining both interventions used in groups
VI and VII. Group IX hearts were ischemically preconditioned as in group II,
and sustained Na+/H+ exchange inhibition during both storage and early reper-
fusion was used as in group VIII.
Results: On the basis of comparisons of postischemic left ventricular con-
tractility and diastolic function, coronary flow, total creatine kinase leakage,
and myocardial water content, values indicative of improved protection were
obtained by combining ischemic preconditioning with Na+/H+ exchange
inhibition by cariporide given during storage and initial reperfusion. The
endothelium-dependent vasodilatory postischemic responses to 5-hydrox-
ytryptamine or acetylcholine and endothelium-independent responses to
papaverine were not affected by these interventions.
Conclusions: These data suggest that cardioprotection conferred by the Na+/H+
exchange inhibitor cariporide is additive to that of ischemic preconditioning and
might effectively contribute to improve donor heart preservation during cardiac
transplantation. (J Thorac Cardiovasc Surg 2001;121:155-62)
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cate the salutary effects of classical ischemic precondi-
tioning.7,8 Although the mechanism of this protection
has not been completely elucidated, there is strong evi-
dence that it involves a reduction of calcium overload.4
During the past years, the reduction of calcium over-
load and related tissue injury has also been the target of
another very effective strategy on the basis of Na+/H+
exchange (NHE) inhibition. This antiport allows the
extrusion of intracellular protons in exchange for sodi-
um ions. However, in the setting of ischemia-reperfu-
sion, the depletion of energy stores leads to a defective
efflux of sodium ions through the ATP-driven Na+-K+
ATPase. The subsequent increase in intracellular sodi-
um results in calcium overload because of increased
calcium influx through the Na+/Ca2+ exchanger. The
above hypothesis is now validated by a number of
experimental studies that have convincingly demon-
strated the efficacy of NHE inhibitors to blunt the
ischemia-reperfusion injury.9 From a surgical stand-
point, this approach is particularly appealing because
of the clinical availability of cariporide, a highly selec-
tive inhibitor of the predominant cardiac isoform of the
exchanger (NHE-1)10 that has achieved a satisfactory
safety record in the GUARDIAN trial.11
The present study was therefore designed to compare
ischemic preconditioning, diazoxide, and cariporide in
a rat model of prolonged cold storage simulating the
situation of cardiac allografts.
Material and methods
Experimental preparation. Male Wistar rats weighing
270 to 330 g were injected intravenously with 0.2 mL (200
UI) heparin and intraperitoneally anesthetized with pentobar-
bital sodium (60 mg/kg). Their hearts were excised and rapid-
ly mounted on a nonrecirculating Langendorff perfusion col-
umn. All animals were cared for in compliance with the
“Guide for the Care and Use of Laboratory Animals” pub-
lished by the National Institutes of Health (NIH publication
No. 86-23, revised 1985).
Retrograde aortic perfusion of isolated hearts was institut-
ed at a constant pressure of 75 mm Hg with ultrafiltered (5-
µm pore filter), oxygenated (95% oxygen and 5% carbon
dioxide), and normothermic (37°C) Krebs-Henseleit solution.
The solution had a pH of 7.3 to 7.4 when gassed. The pul-
monary outflow tract was incised to allow drainage of the
coronary effluent. A catheter was placed through the apex of
the left ventricle to drain the thebesian flow. The left atrium
was opened, and a latex balloon was inserted into the left ven-
tricle. Left ventricular pressure was continuously recorded
online with a pressure transducer (TSD104, BIOPAC
Systems, Inc) connected through the universal interface mod-
ule (UIM100A) to the actual data acquisition unit (MP100A).
Data were processed with a Power Macintosh 6100/66 com-
puter (Apple Computer) using the software AcqKnowledge
III for the MP100WS. Left ventricular developed pressure
(LVDP) was measured as the difference between peak sys-
tolic pressure and left ventricular end-diastolic pressure
(LVEDP). The first derivative (dP/dt) was calculated with the
software. Coronary flow was measured by means of timed
collection of the coronary venous effluent. Left ventricular
pacing was established at a constant rate of 320 beats/min
throughout the control and reperfusion periods.
Experimental time course. The hearts were initially
allowed to equilibrate for 15 minutes after being instrumented,
and stable recordings were established. The left ventricular bal-
loon was inflated to the volume that gave an LVEDP of 8 mm
Hg. After stabilization, systolic and diastolic function was
measured under these isovolumic conditions. In addition, the
left ventricular balloon was inflated in 0.02-mL increments to
construct pressure-volume curves. Two sets of pressure-vol-
ume measurements were generated, the first of which was dis-
carded because of potential small balloon shifts. The zero vol-
ume was defined at the point at which LVEDP was zero.
At the end of the 1-hour control preischemic period, all
hearts were arrested by using 50 mL of Celsior (Imtix-
Sangstat) heart preservation solution delivered through a
sidearm on the aortic cannula at 4°C under a pressure of 45
mm Hg. Hearts were then removed from the Langendorff col-
umn and placed in plastic containers (50 mL) filled with the
same solution and surrounded by crushed ice. They were sub-
sequently stored for 4 hours.
On completion of the storage interval, hearts were trans-
ferred back to the Langendorff column, and the balloon
catheter was reinserted into the left ventricle. The balloon vol-
ume was set to the value that had given a preischemic LVEDP
of 8 mm Hg. Reperfusion was started with normothermic
(37°C) Krebs-Henseleit solution at 45 mm Hg pressure during
the first 15 minutes, and the perfusion pressure was increased
thereafter to 75 mm Hg. Left ventricular pacing was started at
a constant rate of 320 beats/min once a regular spontaneous
heart rhythm had resumed. The coronary effluent was collect-
ed for measurements of total creatine kinase release over the
first 15 minutes of reperfusion. Total creatine kinase activity
was assessed enzymatically with an automatic analyzer
(Olympus). The results are expressed as international units per
gram of dry weight. After 60 and 120 minutes of reperfusion,
pressure-volume curves were generated by incrementally
inflating the left ventricular balloon in 0.02-mL aliquots, and
the first set of each measurement was discarded.
At the end of reperfusion, the ventricles were weighed. Wet
weights were measured after both ventricles were incised and
the excess fluid was blotted. Dry weights were measured
after drying for 24 hours at 80°C. Water content was comput-
ed from the following formula:
100 × (wet weight – dry weight)/wet weight
Experimental groups. The hearts were divided into 9
groups. Group I hearts (n = 12) served as controls and were
only arrested with and stored in Celsior solution. In group II,
hearts (n = 8) were preconditioned by two 5-minute episodes
of total (no flow) global ischemia, each separated by 5 min-
utes of reperfusion before arrest with Celsior solution. Group
III hearts (n = 8) were arrested with and stored in Celsior
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solution supplemented with 100 µmol/L of the mitochondri-
al KATP opener diazoxide. In group IV, hearts (n = 6) received
an infusion of diazoxide (30 µmol/L) during the first 15 min-
utes of reperfusion. Group V hearts (n = 6) underwent a pro-
tocol combining the 2 interventions used in groups III and IV
(ie, diazoxide during both arrest-storage and early reperfu-
sion). In group VI, hearts (n = 7) were arrested with and
stored in Celsior solution supplemented with 1 µmol/L of the
NHE inhibitor cariporide. Group VII hearts (n = 6) received
an infusion of cariporide (1 µmol/L) during the first 15 min-
utes of reperfusion. In group VIII, hearts (n = 6) underwent a
protocol combining the 2 interventions used in groups VI and
VII. Group IX hearts (n = 8) were ischemically precondi-
tioned as in group II, and combined NHE inhibition was used
as in group VIII. This combined treatment regimen was
selected on completion of the preceding experiments showing
that groups II and VIII were those that had separately yielded
the best functional outcome (Table I).
Studies of coronary vasodilatory responses. In groups I,
II, and IX, during the preischemic period and after 60 minutes
of reperfusion, the endothelium-dependent coronary flow
response was tested by a 5-minute perfusion with 5-hydrox-
ytryptamine (5-HT; 10–7 mol/L). Coronary flow was mea-
sured during the last 4 minutes of 5-HT administration. This
was followed by a 12-minute washout perfusion with drug-
free Krebs-Henseleit solution to reestablish baseline coronary
flow. The hearts were subsequently perfused with the endothe-
lium-independent vasodilator papaverine (5 × 10–6 mol/L) for
5 minutes, and the coronary flow was again measured over the
last 4 minutes of this perfusion. The preischemic application
of vasodilatory agonists had no significant influence on the
postischemic functional recovery of hearts in control group I,
and therefore they were also used in groups II and IX.
After 100 minutes of reperfusion, the constant-pressure
heart model was converted to a constant-flow model by using
a calibrated roller pump (Minipuls 2, Gilson). The arterial
pressure was continuously measured with a pressure trans-
ducer (TSD104A) connected through fluid-filled polyethyl-
ene tubing to the aortic cannula. The coronary resistance was
calculated as arterial pressure over coronary flow. After base-
line measurements at constant flow, the coronary bed was
preconstricted by continuous perfusion with prostaglandin
F2α (10–5 mol/L), and the endothelium-dependent coronary
relaxation to acetylcholine (10–6 mol/L) was tested.
Solutions and drugs. The Krebs-Henseleit buffer con-
tained the following: NaCl, 118 mmol/L; KCl, 4.7 mmol/L;
MgSO4, 1.2 mmol/L; NaHCO3, 25 mmol/L; KH2PO4, 1.2
mmol/L; CaCl2, 2.5 mmol/L; and glucose, 11 mmol/L. The
Celsior solution was provided by Imtix-Sangstat and had
the following composition: potassium, 15 mmol/L; sodium,
100 mmol/L; magnesium, 13 mmol/L; calcium, 0.26
mmol/L; chloride, 41.5 mmol/L; histidine, 30 mmol/L; glu-
tamate, 20 mmol/L; lactobionate, 80 mmol/L; mannitol, 60
mmol/L; and reduced glutathione, 3 mmol/L. 5-HT,
papaverine hydrochloride, prostaglandin F2α tris salt, and
acetylcholine hydrochloride were purchased from Sigma
Chemical Co. Diazoxide (Hyperstat) was obtained from
Schering-Plough. Cariporide mesilate (HOE 642) was
obtained from Hoechst Marion Roussel and dissolved in
dimethyl sulfoxide. All drugs were added to Krebs-
Henseleit buffer immediately before use.
Statistical analysis. Functional data were compared by
using 2-factor analysis of variance with repeated measures,
taking treatment as one factor and time as the second factor.
Differences among the various experimental groups at the
same reperfusion time points were tested by using 1-way fac-
torial analysis of variance. Intergroup differences were spec-
ified by using the Student-Newman-Keuls test for multiple
comparisons. Left ventricular compliance curves were
assessed by using linear regression analysis of LVEDP data
to calculate a slope. Preischemic and postischemic coronary
flow responses to 5-HT and papaverine within the same
group were compared by using paired 2-tailed t tests. Data
are reported as the mean ± SD.
Results
Left ventricular diastolic function. Baseline diastolic
data were not significantly different among the 9 groups
(Table I). After 60 minutes of reperfusion, the value of
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Table I. Diastolic and systolic function 
LVEDP (mm Hg) LVDP (mm Hg) LV dP/dt max (mm Hg/s)
Group Baseline Reperfusion Baseline Reperfusion Baseline Reperfusion
Control 8.6 ± 1.0 25.4 ± 6.3 121.4 ± 11.5 72.5 ± 27.3 3346 ± 400 2041 ± 659
Ischemic PC 8.2 ± 0.8 13.2 ± 3.7* 125.9 ± 12.5 81.0 ± 22.1 3487 ± 436 2322 ± 527
Diazoxide (A/S) 8.4 ± 0.9 15.6 ± 8.6 131.9 ± 13.5 82.0 ± 12.9 3510 ± 398 2252 ± 412
Diazoxide (R) 8.7 ± 1.1 25.4 ± 9.2 125.1 ± 17.8 60.1 ± 14.5 3549 ± 530 1761 ± 501
Diazoxide (C) 8.4 ± 0.6 17.8 ± 9.1 129.7 ± 9.2 89.9 ± 15.5 3681 ± 640 2424 ± 470
Cariporide (A/S) 7.8 ± 1.1 16.4 ± 11.6 129.0 ± 5.6 75.3 ± 22.5 3687 ± 301 2348 ± 719
Cariporide (R) 8.2 ± 1.6 25.4 ± 12.7 123.5 ± 12.6 72.4 ± 10.5 3522 ± 565 2183 ± 334
Cariporide (C) 8.5 ± 0.9 12.1 ± 5.9* 127.3 ± 9.7 88.8 ± 17.5 3674 ± 268 2697 ± 606
Ischemic PC + cariporide (C) 8.7 ± 0.9 9.5 ± 1.1† 122.9 ± 9.1 101.6 ± 12.2* 3204 ± 489 2830 ± 486*
Reperfusion values represent the average of values measured at 60 minutes of reperfusion. All values are means ± SD. PC, Preconditioning; A/S, arrest-storage; 
R, reperfusion; C, combined.
*P < .05 versus control, diazoxide (reperfusion), and cariporide (reperfusion).
†P < .01 versus control, diazoxide (reperfusion), and cariporide (reperfusion).
158 Kevelaitis et al The Journal of Thoracic and
Cardiovascular Surgery
January 2001
Fig 1. Left ventricular stiffness. The pressure-volume curves were obtained at baseline (before cardiac arrest) and
after 60 minutes of reperfusion. Baseline data are expressed as a pooled group average. All values are means ±
SEM. PC, Preconditioning. *P = .024 ischemic preconditioning versus control; **P < .001 ischemic precondi-
tioning and cariporide (combined) versus control.
Fig 2. Total creatine kinase leakage during the initial 15 minutes of reperfusion. All values are means ± SD. PC,
Preconditioning; A/S, arrest-storage; R, reperfusion; C, combined. *P = .029 versus control; **P = .004 versus
control.
LVEDP was significantly lower in ischemically precon-
ditioned hearts and hearts treated with cariporide during
storage and early reperfusion compared with control
hearts. The combination of these 2 strategies led to an
additional improvement of left ventricular diastolic func-
tion (Table I). The recovery of left ventricular diastolic
function tended to be improved in hearts treated with
diazoxide during arrest-storage; however, the difference
with control hearts failed to reach the level of statistical
significance (P = .086). Similar patterns were seen when
LVEDP was analyzed in relation to balloon volume and
pressure-volume curves were constructed. The upward
shift of reperfusion LVEDP-volume curves was signifi-
cantly less pronounced in hearts preconditioned with
ischemia or treated with cariporide than in control hearts
(Fig 1). Thus the slopes of pressure-volume curves were
increased from a baseline value of 402 ± 138 mm
Hg/mL to a reperfusion value of 649 ± 202 mm Hg/mL
in control hearts, from 390 ± 93 mm Hg/mL to 420 ± 82
mm Hg/mL in ischemically preconditioned hearts (P =
.024 vs control reperfusion), and from 389 ± 164 mm
Hg/mL to 436 ± 156 mm Hg/mL in hearts treated with
cariporide during arrest-storage and early reperfusion (P
= .079 vs control reperfusion). The coadministration of
ischemic preconditioning and cariporide further reduced
the postischemic slope of pressure-volume curves to 363
± 37 mm Hg/mL (P < .001 vs control reperfusion),
which was not significantly different from the baseline
value of 355 ± 59 mm Hg/mL.
Left ventricular systolic function. Although LVDP
decreased significantly (P < .001) after storage and
reperfusion in all hearts, its highest values were achieved
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Table II. Endothelium-dependent coronary relaxation to acetylcholine (10–6 mol/L)
Coronary vascular resistence 
Coronary flow (mm Hg · mL–1 · min–1 · g–1 dry weight) Relaxation
Group (mL · min–1 · g–1 dry weight) Baseline After PGF2α After ACh to ACh (%)
Control (n = 7) 59.6 ± 4.2 0.96 ± 0.16 1.80 ± 0.63 1.52 ± 0.58 39.6 ± 23.5
Ischemic PC (n = 8) 62.3 ± 6.5 0.94 ± 0.11 1.48 ± 0.17 1.27 ± 0.14 39.9 ± 15.6
Ischemic PC + cariporide 65.4 ± 4.5 0.87 ± 0.11 1.40 ± 0.16 1.17 ± 0.16 43.3 ± 10.6
(C, n = 7)
All experiments were performed after 100 minutes of reperfusion under conditions of constant flow. All values are means ± SD.
ACh, Acetylcholine; PGF2α, prostaglandin F2α (10–5 mol/L); PC, preconditioning; C, combined.
Fig 3. Endothelium-dependent coronary flow response to 5-HT (10–7 mol/L). All values are means ± SD. CF, Coronary
flow; PC, preconditioning. *P < .001 versus preischemia and baseline; **P < .01 versus reperfusion and baseline
(paired 2-tailed t tests); #P = .034 versus control group, reperfusion, and baseline (Student-Newman-Keuls test).
with the combination of ischemic preconditioning with
cariporide given during arrest-storage and initial reperfu-
sion (Table I). An additive effect of ischemic precondi-
tioning and cariporide was apparent in this group, with
LVDP recovery being significantly (P = .016) improved
compared with that of the control group. Treatment-
related effects on postischemic maximum dP/dt grossly
paralleled those on LVDP in all groups (Table I).
Creatine kinase leakage. Total creatine kinase
release during the initial 15 minutes of reperfusion was
significantly (P = .029) lower in ischemically precon-
ditioned hearts than in control hearts (Fig 2). In keep-
ing with functional data, combination of ischemic pre-
conditioning and treatment with cariporide during
storage and initial reperfusion presumably resulted in
additional infarct limitation because creatine kinase
leakage was significantly (P = .004) reduced in this
group compared with that in the control group (Fig 2).
Myocardial water content. The percentage of tissue
water was significantly (P = .042) smaller in ischemi-
cally preconditioned hearts (79.95% ± 0.55%) than in
control hearts (81.1% ± 1.02%). Administration of cari-
poride during storage and early reperfusion significant-
ly reduced myocardial edema compared with that
found in the control group, regardless of whether the
drug was given alone (79.28% ± 0.78%, P = .009) or in
combination with ischemic preconditioning (79.30% ±
0.71%, P = .006).
Coronary vascular responsiveness. Before storage,
administration of 5-HT significantly (P < .001)
increased coronary flow above baseline values (Fig 3).
During reperfusion, 5-HT still elicited a significant
increase in coronary flow, but this endothelium-depen-
dent response was smaller than that obtained before
storage (P < .01 vs reperfusion baseline values). The
endothelium-independent relaxation to papaverine fea-
tured similar patterns (data not shown). In the constant-
flow experiments the endothelium-dependent vasodila-
tory response to acetylcholine was not significantly
different among the groups (Table II).
Discussion 
The salient findings of this study are as follows: (1)
ischemic preconditioning improves preservation of
cold-stored rat hearts; (2) there was a trend for this pro-
tection to be closely duplicated by pharmacologic inter-
ventions targeted at opening mitochondrial KATP chan-
nels (diazoxide), inhibiting NHE (cariporide), or both;
and (3) the highest values of efficacy end points were
found when ischemic preconditioning was combined
with NHE inhibition.
Ischemic preconditioning resulted in a better recov-
ery of function than that found in control hearts. This
improvement was primarily manifested as a decrease in
reperfusion end-diastolic pressures and creatine kinase
leakage, thereby supporting the idea that the salutary
effects of preconditioning on functional outcome are
primarily mediated by a reduction in cell necrosis.1,8
Ischemic preconditioning is thought to cause a protein
kinase C–mediated activation of mitochondrial KATP
channels.12 It is postulated that the entry of K+ through
these open channels dissipates the membrane potential
normally established across the inner mitochondrial
membrane by the proton pump. This in turn should
decrease the driving force for mitochondrial calcium
uptake,4 which is a major determinant of postischemic
functional recovery.13 This hypothesis is consistent
with the ability of preconditioning to reduce calcium
overload14 and the related contracture, as shown in the
present study. An additional contributor to this preser-
vation of diastolic function could be the limitation of
myocardial edema yielded by our group of precondi-
tioned hearts. A likely mechanism is the reduction of
intracellular acidosis, which is a major metabolic con-
sequence of ischemic preconditioning14 and is expect-
ed to slow NHE activity.15 This hypothesis is support-
ed by the finding that preconditioning reduces the
intracellular accumulation of Na+,14 which in turn
should limit water influx. It is also possible that the bet-
ter preservation of high-energy phosphates resulting
from preconditioning may allow a more effective func-
tioning of the ATP-driven Na+-K+ ATPase,16 but such a
mechanism is expected to be transient because precon-
ditioning has been shown to decrease the rate of ATP
depletion only during the early phase of ischemia.14
Finally, our findings that endothelium-dependent coro-
nary responses were unaffected by preconditioning are
consistent with previous observations that the protec-
tion afforded by preconditioning to myocytes does not
extend to endothelial cells.8,17
The addition of diazoxide to the storage solution
closely duplicated the beneficial effects of precondi-
tioning on postischemic function. The drug was used at
a concentration that has been reported to confer maxi-
mal cardioprotection.5 Because this dose is yet 8-fold
lower than that required for opening sarcolemmal KATP
channels,18 it is reasonable to attribute the effects of dia-
zoxide to a selective opening of the mitochondrial KATP
channels, which supports the role of these channels as
mediators of the cardioprotective effects of ischemic
preconditioning.4 That the protection conferred by dia-
zoxide involved a reduction of calcium overload subse-
quent to channel opening is supported by a recent
study19 showing that exposure of cold-stored rat hearts
to nicorandil, a drug that shares with diazoxide the abil-
ity to activate mitochondrial KATP channels,20 markedly
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reduces intracellular calcium accumulation during
reperfusion. Basically, the patterns of improvement
yielded by supplementation of diazoxide to the storage
solution parallel those reported in our previous study,8
in which diazoxide was given before storage according
to a preconditioning protocol. This observation is at
variance with the recent study of Baines and colleagues7
in which diazoxide administered after the onset of coro-
nary artery occlusion failed to reduce infarct size. This
discrepancy, however, can be explained by several dif-
ferences in the experimental design, including dosing,
route and duration of drug administration, and selected
end point. That diazoxide can remain effective when
given into the ischemic period is consistent with its
direct effect on mitochondrial KATP channels, which
allow bypass of the upstream protein kinase C–mediat-
ed signaling pathway triggered by classical ischemic
preconditioning.12 In addition, this observation bears
some clinical relevance because this drug exerts marked
hypotensive effects7 so that its prearrest administration
could conceivably worsen the hemodynamic instability
that is common at the time of donor heart harvest. This
issue is obviously addressed by direct drug supplemen-
tation to the arrest-storage medium. However, in con-
trast to the good results yielded by this treatment proto-
col, administration of diazoxide during the sole period
of early reperfusion resulted, in the present study, in a
loss of protection. In addition to a reduction of calcium
overload, another effect of mitochondrial KATP channel
opening is matrix swelling and reduced ATP synthesis.4
Although such an effect can be protective during
ischemia because it limits energetic waste, it may con-
ceivably become undesirable at the time of reperfusion
when an effective workload has to be reestablished and
could consequently have accounted for the failure of
postischemic diazoxide treatment to improve recovery
over that of control hearts.
The administration of cariporide during either arrest-
storage or early reperfusion yielded results equivalent
to those of diazoxide, and only a combined administra-
tion protocol provided better cardioprotection. In fact,
for 2 major end points (left ventricular diastolic func-
tion and myocardial edema), the effects of cariporide
added to the arrest-storage solution and the initial
reperfusate matched those of ischemic preconditioning.
A previous study by Tritto and colleagues21 has docu-
mented similar patterns of improvement in cardioplegi-
cally arrested hearts exposed to cariporide and further
demonstrated a significant correlation between the gain
in myocardial water content and the functional out-
come. Thus these data and ours support the view that
NHE is operative during ischemia, as well as under
hypothermic conditions.22 However, the activity of the
exchanger is expected to become still more operative at
the time of reperfusion, when its potential blockade by
extracellular acidosis is suddenly relieved. In addition
to limiting sodium-driven calcium overload, NHE inhi-
bition prevents the intracellular alkaline overshoot
occurring during early reperfusion23 and the related
hypercontracture of myofilaments,24 which should con-
tribute to preservation of postischemic function. It is
noteworthy that the initial decrease in intracellular pH
is temporally linked to the limitation of reperfusion
contracture. Taken together, these data provide a strong
rationale for blocking NHE activity during both
ischemia and reperfusion. The salutary effects of max-
imizing the duration of exposure of myocardial tissue
to NHE inhibitors have been previously demonstrated
under normothermic conditions21 and are further sup-
ported by our data showing superior cardioprotection
when cariporide was added to both the arrest-storage
solution and the initial reperfusate. It should finally be
noted that although these results were obtained in an
isolated heart model, their clinical relevance is
strengthened by the findings that NHE inhibitors exert
similar cardioprotective effects in large animal models
of orthotopic transplantation.25
The combination of ischemic preconditioning with
cariporide given during both arrest-storage and early
reperfusion resulted in the greatest degree of cardio-
protection among all treatment regimens, even though
differences did not consistently achieve statistical sig-
nificance, possibly because of the large number (9) of
experimental groups and the use of adjustment for mul-
tiple comparison analysis. In particular, these hearts
demonstrated a lesser degree of reperfusion contracture
and creatine kinase release than those receiving either
intervention alone; enzyme leakage, for example, was
reduced by 52% and 71% compared with precondition-
ing alone and cariporide alone, respectively. These
hearts also had significantly higher postischemic con-
tractile indices and basal coronary flows than control
hearts. These data support previous studies showing
that ischemic preconditioning and NHE inhibition
exert additive protective effects, particularly after pro-
longed ischemic injury,22 regardless of the type of
inhibitor (an amiloride derivative in the study of Bugge
and colleagues26 or a benzoylguanidine-based drug like
cariporide in the study of Shipoli and colleagues22) and
the end point of injury (infarct size26 or left ventricular
function22). Taken together, these data suggest that
ischemic preconditioning and NHE inhibition elicit
cardioprotection through different mechanisms.
Although the present data do not allow further dissec-
tion of the mechanism by which each intervention
elicited cardioprotection, it is noteworthy that the
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reduction of postischemic myocardial edema in cari-
poride-treated hearts was similar irrespective of
whether preconditioning was used, whereas only
ischemically preconditioned hearts featured a signifi-
cant reduction of postischemic creatine kinase release,
regardless of whether they had been previously
exposed to cariporide. This supports the view that pre-
conditioning primarily exerts infarct-limiting effects,
whereas NHE inhibition may also act on the stunning
component of postischemic cardiac dysfunction.26 The
combination of anti-infarct and antistunning effects
would then account for our finding that hearts exposed
to preconditioning and cariporide were the only ones to
yield a significant improvement of contractile indices
compared with control hearts. We acknowledge, how-
ever, that these assumptions are based on data obtained
in a buffer-perfused isolated rat heart model and, con-
sequently, require validation in a more physiologically
relevant, blood-perfused, large animal preparation.
In conclusion, our data show that maximal cardio-
protection can be conferred to cold-stored rat hearts by
combining ischemic preconditioning with NHE inhibi-
tion by cariporide given in a sustained fashion through-
out the period of ischemia and during early reperfusion.
Future studies are warranted to assess whether and how
the additional component of protection provided by
ischemic preconditioning can be duplicated by a clini-
cally relevant pharmacologic intervention.
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